Evidence map›Paper›PMID 39544107›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Tuberculosis Preventive Treatment for Pregnant People With HIV in South Africa: A Modeling Analysis of Clinical Benefits and Risks.

Linzy V Rosen, Acadia M Thielking, Caitlin M Dugdale, Grace Montepiedra, Emma Kalk, Soyeon Kim, Sylvia M LaCourse, Jyoti S Mathad, Kenneth A Freedberg, C Robert Horsburgh and 4 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Linzy V RosenMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Acadia M ThielkingMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Caitlin M DugdaleMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-6604-6111
Grace MontepiedraDepartment of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0002-6866-4335
Emma KalkCentre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, Cape Town, Western Cape, South Africa.ORCID 0000-0001-7706-6866
Soyeon KimFrontier Science Foundation, Brookline, Massachusetts, USA.ORCID 0000-0002-4776-6092
Sylvia M LaCourseDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9809-5997
Jyoti S MathadDepartment of Medicine, Center for Global Health, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.ORCID 0000-0001-9487-7775
Kenneth A FreedbergMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-3143-7822
C Robert HorsburghBoston University School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-6838-7895
A David PaltielPublic Health Modeling Unit, Yale School of Public Health, New Haven, Connecticut, USA.ORCID 0000-0002-4861-3290
Robin WoodDesmond Tutu Health Foundation, Mowbray, Cape Town, Western Cape, South Africa.ORCID 0000-0002-4276-7117
Andrea L CiaranelloMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4268-3263
Krishna P ReddyMedical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-1832-2193

Funding

Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
Optimizing HIV Care in Less Developed CountriesR01AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Emily Parker Hyle · 2004 to 2026
$21.5M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Optimizing HIV Care in Less Developed CountriesR37AI058736 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FREEDBERG, KENNETH ALAN · 2018 to 2024
$6.6M
Reaching for the end of pediatric AIDS: Modeling strategies to strengthen the maternal-child HIV care continuum and eliminate vertical HIV transmission.R37HD079214 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI Andrea Lynne Ciaranello · 2024 to 2026
$3.0M
Modeling the Effects of HIV, Chlamydia, and Gonorrhea in Mother-Infant Pairs in Botswana.K08HD101342 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI DUGDALE, CAITLIN · 2020 to 2024
$897k
INnovative data Science to Impact the TB Epidemic - INSITEU01TW012626 · FIC · UNIVERSITY OF CAPE TOWN · PI KALK, EMMA KATE · 2023 to 2025
$742k
FIC NIH HHS U01 TW012626MGH James and Audrey Foster Research Scholar AwardNIAID NIH HHS R01 AI058736NIAID NIH HHS R01 AI093269NIAID NIH HHS R37 AI058736NIAID NIH HHS UM1 AI068616NICHD NIH HHS K08 HD101342NICHD NIH HHS R37 HD079214NIH HHS U01 TW012626
6 · The paper itself

Abstract

backgroundAlthough prior studies of tuberculosis-preventive treatment (TPT) for pregnant people with human immunodeficiency virus (PPWH) report conflicting adverse pregnancy outcome (APO) risks, international guidelines recommend TPT for PPWH.

methodsWe used a microsimulation model to evaluate 5 TPT strategies among PPWH receiving antiretroviral therapy in South Africa: No TPT; 6 months of isoniazid (6H) or 3 months of isoniazid-rifapentine (3HP) during pregnancy (Immediate 6H or Immediate 3HP) or post partum (Deferred 6H or Deferred 3HP). The primary outcomes were maternal, fetal/infant, and combined deaths from causes potentially influenced by TPT (maternal tuberculosis, maternal hepatotoxicity, stillbirth, low birth weight [LBW], and infant tuberculosis). Tuberculosis during pregnancy confers 250% and 81% higher modeled risks of stillbirth and LBW, respectively. In lower-risk or higher-risk scenarios, immediate TPT confers 38% lower or 92% higher risks of stillbirth and 16% lower or 35% higher risks of LBW.

resultsImmediate TPT would minimize deaths among PPWH. When TPT confers higher stillbirth and LBW risks, immediate TPT would produce the most combined maternal and fetal/infant deaths, even with low maternal CD4 cell count and high tuberculosis incidence. If immediate TPT yields a <4% or <20% increase in stillbirth or LBW, immediate TPT would produce fewer combined deaths than deferred TPT (sensitivity analysis range, <2%-22% and <11%-120%, respectively).

conclusionsIf APO risks are below identifiable thresholds, TPT during pregnancy could decrease combined maternal and fetal/infant deaths. Given uncertainty around isoniazid's risks, and the low threshold at which APO risks could outweigh benefits from tuberculosis deaths averted, studies of newer TPT regimens among PPWH are warranted to inform guidelines.

Indexed as

Antitubercular AgentsHIV InfectionsPregnancy Complications, InfectiousTuberculosisAdultAnti-HIV AgentsChemopreventionFemaleHumansInfant, NewbornIsoniazidPregnancyPregnancy OutcomeRifampinRisk AssessmentSouth AfricaAnti-HIV AgentsAntitubercular AgentsIsoniazidRifampinrifapentineadverse pregnancy outcomeHIVpregnancytuberculosistuberculosis preventive treatment

Identifiers

PMID39544107
PMCPMC12497950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.